Diabetic Macular Edema News and Research

RSS
Fluid can leak into the center of the macula, the part of the eye where sharp, straight-ahead vision occurs. The fluid makes the macula swell, blurring vision. This condition is called macular edema. It can occur at any stage of diabetic retinopathy, although it is more likely to occur as the disease progresses. About half of the people with proliferative retinopathy also have macular edema.
Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Hercules Technology Growth Capital issues advance payment to Alimera Sciences

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

Alimera announces FDA approval of ILUVIEN for treatment of diabetic macular edema

EYLEA Injection gets approval in Japan for treatment of myopic CNV

EYLEA Injection gets approval in Japan for treatment of myopic CNV

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

FDA grants Breakthrough Therapy designation to EYLEA Injection for treatment of diabetic retinopathy

New way to reduce abnormal blood vessel growth and leakage in eye

New way to reduce abnormal blood vessel growth and leakage in eye

iCo Therapeutics reports financial results for second quarter 2014

iCo Therapeutics reports financial results for second quarter 2014

Research demonstrates that African Americans bear heavier burden of DME

Research demonstrates that African Americans bear heavier burden of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

iCo reports study results of Oral Amp B drug candidate targeting latent HIV reservoirs

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron announces FDA approval of EYLEA Injection for DME treatment

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Italian Medicines Agency grants marketing authorization to ILUVIEN for chronic DME treatment

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Bayer HealthCare seeks EU marketing authorization of EYLEA for macular edema following BRVO

Medicare to pay for hep C screenings for baby boomers

Medicare to pay for hep C screenings for baby boomers

First Edition: June 3, 2014

First Edition: June 3, 2014

Study shows high BP drugs may raise likelihood of age-related macular degeneration

Study shows high BP drugs may raise likelihood of age-related macular degeneration